NFATC4

Across TCGA pan-cancer cohorts, NFATC4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NFATC4 data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher NFATC4 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated NFATC4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, THYM, and THCA are the cancer types where NFATC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.432	.005	28	view →
THYM	OS	Median	All	0.604	0.975	<.001	24	view →
THCA	DFS	Median	All	0.082	0.841	<.001	12	view →
GBM	DFS	Median	All	1.000	0.204	.042	6	view →
LUSC	DFS	Median	II,III,IV	0.414	0.725	.004	6	view →
SKCM	DFS	Median	II,III,IV	0.457	0.718	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NFATC4–UCEC (DFS)

Open the UCEC breakdown →